Enovix to buy South Korean battery maker in cash and stock deal
Shares of Enovix Corp. (ENVX) rose more than 1% in the extended session Wednesday after the battery maker said it has agreed to buy privately held Korean battery maker Routejade in a cash and stock deal. Enovix will pay $16.5 million in cash and about 6.2 million of its shares for the company. "The acquisition provides Enovix with vertical integration of electrode coating and battery-pack manufacturing while adding an established lithium-ion battery business with factories in Korea, along with complementary products, customers, and suppliers," the Fremont, Calif., company said in a statement. The deal is expected to close in the fourth quarter and it will be "immediately accretive," Enovix said. Routejade brings more than 20 years of experience as a manufacturer and supplier of lithium-ion batteries in end markets such as wearables, medical, industrial, and the South Korean military, Enovix said. Shares of Enovix ended the regular trading day down 5.4%.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-20-23 1643ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters